Clinical observation of different doses of rituximab for the treatment of severe pemphigus: A single-center prospective cohort study

Name: Clinical observation of different doses of rituximab for the treatment of severe pemphigus: A single-center prospective cohort study
Creator: Jiao Zhang
Published: 2022-06-27T15:26:08.740Z
Keywords: Dermatology, Rituximab, Prospective Cohort Study, Pemphigus, Bullous Disease

Zhang, Jiao; Huang, Xueyi; Zhang, Zeqiao; Zhao, Peizhen; Chen, Wenjing; Liang, Yunsheng; Liu, Hongfang; Zhong, Zemin; Chen, Yongfeng

doi:10.17632/v4hb3cp7zt.1

Clinical observation of different doses of rituximab for the treatment of severe pemphigus: A single-center prospective cohort study

Published: 27 June 2022| Version 1 | DOI: 10.17632/v4hb3cp7zt.1

Contributors:

Jiao Zhang, Xueyi Huang, Zeqiao Zhang, Peizhen Zhao, Wenjing Chen, Yunsheng Liang, Hongfang Liu, Zemin Zhong, Yongfeng Chen

Description

Clinical observation of different doses of rituximab for the treatment of severe pemphigus: A single-center prospective cohort study Supplemental Figure 1 (A, B) Percentage of peripheral B and T lymphocytes. (C, D) Anti-desmoglein (Dsg) 1 and Dsg 3 enzyme-linked immunosorbent assay (ELISA) indices. The dashed line in panels C and D represents the cutoff values proposed by the manufacturer for the anti-Dsg 1 and Dsg 3 antibodies.

Clinical observation of different doses of rituximab for the treatment of severe pemphigus: A single-center prospective cohort study

Description

Files

Categories

Licence